hexaxim

Hexaxim is a fully liquid, hexavalent combination vaccine used for the immunization of infants and toddlers against six serious infectious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), hepatitis B, and invasive diseases caused by Haemophilus influenzae type b. The vaccine contains inactivated or toxoid forms of the causative agents—diphtheria toxoid, tetanus toxoid, acellular pertussis antigens (pertussis toxoid and filamentous haemagglutinin), hepatitis B surface antigen, inactivated poliovirus types 1-3, and Haemophilus influenzae type b polysaccharide conjugated to tetanus protein. Hexaxim works by inducing the production of protective antibodies against these pathogens. It is administered as a primary series and booster dose starting from six weeks up to 24 months of age. Developed through an extensive clinical program demonstrating favorable safety and immunogenicity profiles across diverse populations—including preterm infants and those born to Tdap-vaccinated mothers—Hexaxim has been widely adopted globally since its first approval in 2012[1][4][6].

Brand names

Hexaxim

Other names

DTaP-IPV-HB-HibDTPA-hepB-IPV-Hib